Paul Peter Tak received his medical degree from VU Amsterdam and was trained as an internist and immunologist at Leiden University Medical Center, where he also received his PhD. He worked as a scientist at the University of California San Diego and next served as Professor of Medicine and Chair of the Department of Clinical Immunology and Rheumatology at the Academic Medical Centre/University of Amsterdam (AMC). Paul Peter has published extensively in peer-reviewed journals (~600 publications, H-index 144), received numerous awards, has been elected Fellow of the Academy of Medical Sciences, and his leadership was recognized by PharmaVOICE100 and the Medicine Maker Power List. At GlaxoSmithKline he served as Senior Vice President, Chief Immunology Officer, and Global Development Leader. Next, he has been Venture Partner at Flagship Pioneering. In September 2020 he became President and CEO of Candel Therapeutics ($CADL), focused on the development of multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer.